Cofece, Mexico’s antitrust commission, objected to the merger of the pharmaceutical companies Sanofi and Boehringer Ingelheim International in the animal health sector, considering that competition in five animal vaccine markets in Mexico would be at risk.
The agency said that the proposed merger consists of Boehringer acquiring the animal health business that Sanofi operates in Mexico, a transaction that is part of an international transaction agreed on by both companies.
Cofece explained that in this merger, both companies agreed on the commercialization of various vaccines and medicines indicated for poultry, pigs, cattle, goats and sheep, and others.
To ensure that competitive conditions will remain in all five markets, Cofece ruled that the transaction would only be authorized if the companies agreed to the divestment of four Boehringer and one Sanofi vaccine to a third party.
Full Content: El Economista
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI